Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3889468 | 0.77 | TSHR (0.52) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL15307443 | 0.77 | — | — | |
| SCHEMBL11696718 | 0.77 | PPARD (0.50) | TSHRPPARDTP53TDP1 | |
| SCHEMBL7891394 | 0.75 | — | — | |
| SCHEMBL4971866 | 0.75 | TSHR (0.71) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL13529619 | 0.73 | TSHR (0.48) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL3485999 | 0.72 | TSHR (0.60) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL282085 | 0.72 | TSHR (0.60) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL29099484 | 0.72 | TSHR (0.65) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL7972024 | 0.72 | TSHR (0.46) | TSHRPPARDTP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400793-A1 | COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF | MOMENTIVE PERFORMANCE MATERIALS INC. | 2024-12-05 | — | — | US | claimed |
| CN-118434796-A | Composition for polyurethane foam, foam prepared therefrom and method thereof | 迈图高新材料公司 | 2024-08-02 | — | — | CN | claimed |
| EP-4396271-A1 | COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF | Momentive Performance Materials Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| CN-116987116-B | Continuous synthesis method of diethyl methylthiomethyl phosphate | 常州合全药业有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-116987116-A | Continuous synthesis method of diethyl methylthiomethyl phosphate | 常州合全药业有限公司 | 2023-11-03 | — | — | CN | claimed |
| WO-2023034354-A1 | COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2023-03-09 | — | — | WO | claimed |
| US-8062816-B2 | Phosphonate hole blocking layer photoconductors | XEROX CORPORATION (US) | 2011-11-22 | — | — | US | claimed |
| US-8053151-B2 | Phosphonate containing photoconductors | XEROX CORPORATION (US) | 2011-11-08 | — | — | US | claimed |
| US-20090325091-A1 | PHOSPHONATE CONTAINING PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-12-31 | — | — | US | claimed |
| US-20090297967-A1 | PHOSPHONATE HOLE BLOCKING LAYER PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-12-03 | — | — | US | claimed |
| EP-2128709-A1 | Phosphonate Hole Blocking Layer Photoconductors | Xerox Corporation (US) | 2009-12-02 | — | — | EP | claimed |
| US-20260135164-A1 | LITHIUM SECONDARY BATTERIES CAPABLE OF SELF-POISONING | PROLOGIUM TECHNOLOGY CO., LTD. (TW) | 2026-05-14 | — | — | US | disclosed |
| EP-4668366-A1 | LITHIUM SECONDARY BATTERY CAPABLE OF SELF-POISONING | Prologium Technology Co., Ltd. (TW) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025073792-A1 | WRN INHIBITORY COMPOUNDS | FORX THERAPEUTICS AG (CH) | 2025-04-10 | — | — | WO | disclosed |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| EP-0756625-A1 | IRREVERSIBLE CYSTEINE PROTEASE INHIBITORS CONTAINING VINYL GROUPS CONJUGATED TO ELECTRON WITHDRAWING GROUPS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1997-02-05 | — | — | EP | disclosed |
| WO-1995023222-A1 | IRREVERSIBLE CYSTEINE PROTEASE INHIBITORS CONTAINING VINYL GROUPS CONJUGATED TO ELECTRON WITHDRAWING GROUPS | KHEPRI PHARMACEUTICALS, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| US-4388237-A | NEUROLEPTIC, SEDATIVE, HYPNOTIC, ANALGESIC, ANTIDEPRESSANT | BASF AKTIENGESELLSCHAFT (DE) | 1983-06-14 | — | — | US | disclosed |
| EP-0063489-A1 | 4\"-Modified methylene oleandomycins | PFIZER INC. (US) | 1982-10-27 | — | — | EP | disclosed |
| US-4336368-A | 4 Deoxy-4-methylene oleandomycin and derivatives thereof | PFIZER INC. (US) | 1982-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260135164-A1 | LITHIUM SECONDARY BATTERIES CAPABLE OF SELF-POISONING | L3MBTL3, HAO2, LDHB | TSHR 3143/4885PPARD 4441/4885TP53 553/4885 |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | TSHR 2577/4885PPARD 2857/4885TP53 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.